AR063011A1 - Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico - Google Patents

Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico

Info

Publication number
AR063011A1
AR063011A1 ARP070104260A ARP070104260A AR063011A1 AR 063011 A1 AR063011 A1 AR 063011A1 AR P070104260 A ARP070104260 A AR P070104260A AR P070104260 A ARP070104260 A AR P070104260A AR 063011 A1 AR063011 A1 AR 063011A1
Authority
AR
Argentina
Prior art keywords
therapy
growth factor
epidermal growth
therapeutic compositions
receiver
Prior art date
Application number
ARP070104260A
Other languages
English (en)
Inventor
Rodriguez Rolando Perez
Gomez Audry Fernandez
Molina Luis Enrique Fernandez
Hidalgo Greta Garrido
Ramirez Belinda Sanchez
Requena Alejandro Lopez
Delgado Irene Beausoleil
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40223744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR063011(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of AR063011A1 publication Critical patent/AR063011A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion describe composiciones terapéuticas específicas, que aumentan la eficacia de la terapia con anticuerpos monoclonales (AcMs)contra el receptor del Factor de Crecimiento Epidérmico (EGFR, del inglés "epidermal growth factor receptor") e interferones (INFs de tipo I (alfa/beta).
ARP070104260A 2006-09-29 2007-09-26 Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico AR063011A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060190A CU23612A1 (es) 2006-09-29 2006-09-29 Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico

Publications (1)

Publication Number Publication Date
AR063011A1 true AR063011A1 (es) 2008-12-23

Family

ID=40223744

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104260A AR063011A1 (es) 2006-09-29 2007-09-26 Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico

Country Status (19)

Country Link
US (1) US20100047207A1 (es)
EP (1) EP2070547B1 (es)
KR (1) KR101482957B1 (es)
CN (2) CN102940883A (es)
AR (1) AR063011A1 (es)
AU (1) AU2007302429B2 (es)
BR (1) BRPI0717142A2 (es)
CA (1) CA2664795C (es)
CL (1) CL2007002797A1 (es)
CO (1) CO6160338A2 (es)
CR (1) CR10753A (es)
CU (1) CU23612A1 (es)
MA (1) MA30811B1 (es)
MX (1) MX2009003159A (es)
PE (1) PE20080674A1 (es)
TN (1) TN2009000104A1 (es)
TR (1) TR200902344T1 (es)
UY (1) UY30616A1 (es)
WO (1) WO2008037225A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010014543A (es) * 2008-06-20 2011-04-05 Centro Inmunologia Molecular Inhibidores del receptor del factor de crecimiento epidermico con accion citostatica y sus usos en la terapia de tumores.
CN103536917B (zh) * 2013-10-30 2015-03-11 苏州丁孚靶点生物技术有限公司 干扰素在治疗肿瘤中的用途及相关的产品和方法
MY188446A (en) * 2015-07-27 2021-12-09 Innocimab Pte Ltd Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
RU2129437C1 (ru) * 1992-02-10 1999-04-27 Интерферон Сайнс Инк. Композиция альфа-интерферона и способ ее получения из лейкоцитов крови человека
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
CN1507355A (zh) * 2001-05-08 2004-06-23 Ĭ��ר�����޹�˾ 使用抗egfr抗体和抗激素剂的联合疗法
US20060134064A1 (en) * 2004-12-20 2006-06-22 David Goldstein Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions

Also Published As

Publication number Publication date
CO6160338A2 (es) 2010-05-20
US20100047207A1 (en) 2010-02-25
EP2070547A1 (en) 2009-06-17
UY30616A1 (es) 2008-05-02
WO2008037225A1 (es) 2008-04-03
TN2009000104A1 (en) 2010-08-19
CA2664795A1 (en) 2008-04-03
CA2664795C (en) 2014-06-17
AU2007302429B2 (en) 2013-10-03
KR20090058566A (ko) 2009-06-09
CL2007002797A1 (es) 2008-04-18
MA30811B1 (fr) 2009-10-01
TR200902344T1 (tr) 2009-08-21
KR101482957B1 (ko) 2015-01-15
EP2070547B1 (en) 2013-04-24
AU2007302429A1 (en) 2008-04-03
BRPI0717142A2 (pt) 2013-10-15
EP2070547A4 (en) 2011-11-02
CU23612A1 (es) 2010-12-08
CN101678099A (zh) 2010-03-24
CR10753A (es) 2009-10-15
PE20080674A1 (es) 2008-07-23
MX2009003159A (es) 2009-04-06
CN102940883A (zh) 2013-02-27

Similar Documents

Publication Publication Date Title
AR112564A2 (es) Anticuerpos humanizados contra el receptor del linfoma de burkitt (anti-cxcr5)
UY30525A1 (es) Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
CR20110526A (es) Anticuerpos anti - tnf - alfa y sus usos
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
UY33222A (es) Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
GT201200258A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CL2008003788A1 (es) Composicion farmaceutico que comprende a) el anticuerpo b-ly1 humanizado (anti-cd20/antigeno de referenciacion restringida del linfocito b humano/bp35, de tipo ii), b) opcionalmente de 0,001% al 1%p/v de por lo menos un surfactante, y c) de 1 a 100 mm de un tampon; uso para tratar enfermedades relacionadas con cd20.
GT201200189A (es) Antagonistas de pcsk9
PA8846101A1 (es) Anticuerpos del receptor ii anti-tgf-beta
NZ607996A (en) Substituted nucleotide analogs
BR112012019098B8 (pt) anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
GT200500187A (es) Moduladores de andrògenos
CO2022002622A2 (es) Anticuerpos anti-cd73 y composiciones
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
BR112012028445A2 (pt) compostos de heteroarila bicíclica como moduladores de gpr119
CR20120508A (es) PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES
GT200600156A (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
BR112012021334A2 (pt) material biodegradável, contendo silício, para terapia anti-inflamatória.

Legal Events

Date Code Title Description
FB Suspension of granting procedure